Félix-Ponce M, Jiménez-Gracia AI, Medina-Batalla AL, Kim-Morales D, Abrego-Fernández JÁ, Laniado-Laborín R

Language: Spanish
References: 13
Page: 276-279
PDF size: 161.28 Kb.

ABSTRACT

Background: The treatment of multidrug-resistant tuberculosis (MDR-TB) has traditionally been unsuccessful. This is a multifactorial problem influenced by the poor effectiveness of some of the drugs in the scheme, loss to follow-up and adverse reactions to drugs. Linezolid is a drug that has been shown to be effective in patients with drug-resistant TB, but it has been little used in Mexico because of its high cost and high rate of adverse effects reported in the literature. Material and methods: Retrospective analysis of cases treated with linezolid due to drug-resistant tuberculosis or adverse reaction in a clinic specializing in tuberculosis. Results: In 11 patients who received linezolid due to drug-resistant tuberculosis or mycobacteriosis, we found only one case with an adverse reaction (anemia) that responded to treatment with erythropoietin. Conclusions: Adverse reactions with linezolid at doses of 600 mg/day in our limited experience were uncommon (9%).

REFERENCES

1. WHO. Global Tuberculosis Report 2017. World Health Organization 2017. WHO/HTM/TB/2017.23.

2. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.

3. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367(16):1508-1518. doi: 10.1056/NEJMoa1201964.

4. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015;7(4):603-615. doi: 10.3978/j.issn.2072-1439.2015.03.10.

5. Migliori GB, Eker B, Richardson MD, et al.; TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34(2):387-393. doi: 10.1183/09031936.00009509.

6. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. WHO/HTM/TB/2016.04. ISBN 978 92 4 154963 9.

7. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrugresistant (MDR) and extensively drugresistant (XDR) tuberculosis: a systematic review and metaanalysis. Ann Clin Microbiol Antimicrob 2016;15(1):41. doi: 10.1186/s12941-016-0156-y.

8. http://www.stoptb.org/gdf/drugsupply/pc3.asp?PID=1069

9. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45(1):161-170. doi: 10.1183/09031936.00035114.

10. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40(6):1430-1442. doi: 10.1183/09031936.00022912.

11. Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther 2016;14(10):901-915. doi: 10.1080/14787210.2016.1225498.

12. Laniado-Laborín R. Adverse effects and toxicity of antituberculosis drugs. In: Laniado-Laborín R, editor. Drug Resistant Tuberculosis-Practical Guide for Clinical Management. United Arab Emirates: Bentham Publishers; 2015. p. 78-79.

13. Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig 2017;37(5):423-437. doi: 10.1007/s40261-017-0498-z.